NVDA
NVIDIA Corporation
NVDA has the edge over TBCH overall, supported by stronger fundamentals and stronger valuation.
TBCH
Turtle Beach Corporation
TBCH's outlook is improving, though it still trails on the overall score.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
TBCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Strong | |
| Weak |
TBCH's cash flow is currently strong, and its revenue is stable, but its profitability and balance sheet are under pressure.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
TBCH PE Valuation
TBCH has no meaningful PE right now: it lost money over the past year.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
TBCH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
TBCH has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over TBCH on earnings quality, reporting a profit while its opponent remains loss making.
TBCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.16 | — |
| Q3 2026 | -$0.06 | -107% |
| Q2 2026 | -$0.22 | -123% |
| Q1 2026 | $0.02 | -97% |
| Q4 2025 | $0.77 | -1.3% |
| Q3 2025 | $0.87 | +200% |
| Q2 2025 | $0.95 | +$1.03 |
| Q1 2025 | $0.74 | +$1.40 |
| Q4 2024 | $0.78 | +$1.85 |
TBCH has swung to a loss: it lost $0.06 per share over the past year, after a profit the year before.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over TBCH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over TBCH on profitability, with a higher operating margin.
TBCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $84.7M | +5.3% |
| Q2 2026 | $56.4M | -0.7% |
| Q1 2026 | $42.2M | -34% |
| Q4 2025 | $118.8M | -19% |
| Q3 2025 | $80.5M | -15% |
| Q2 2025 | $56.8M | -26% |
| Q1 2025 | $63.9M | +14% |
| Q4 2024 | $146.1M | +47% |
TBCH's revenue is recovering but still below its 2024 peak: $85M last quarter, up 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | +0.3 points |
| Q2 2026 | -5.4% | -4.8 points |
| Q1 2026 | -33% | -36 points |
| Q4 2025 | 18% | +1.6 points |
| Q3 2025 | 6.7% | -0.1 points |
| Q2 2025 | -0.6% | +4.8 points |
| Q1 2025 | 2.4% | +13 points |
| Q4 2024 | 16% | +7.6 points |
TBCH's operating margin was 7% last quarter, about level with the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over TBCH on cash flow, with more consistent year-over-year improvement.
TBCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.3M | +$8.5M |
| Q2 2026 | $5.9M | +$9.4M |
| Q1 2026 | $29.1M | -28% |
| Q4 2025 | $13.1M | +2.3% |
| Q3 2025 | -$15.9M | +$8.7M |
| Q2 2025 | -$3.5M | +$10.4M |
| Q1 2025 | $40.3M | +52% |
| Q4 2024 | $12.8M | -32% |
TBCH usually generates cash, though not every quarter: the latest was −$7M, but it generated $41M over the past year.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
TBCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.1% | -985K shares |
| 1 year | -11% | -2.2M shares |
| 3 years | +4.9% | +852K shares |
| 5 years | -0.8% | -138K shares |
| Available history | +16% | +2.5M shares |
TBCH has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $25M |
| Q1 2026 | $2.2M |
| Q4 2025 | $2M |
| Q3 2025 | $10.3M |
| Q2 2025 | $5M |
| Q1 2025 | $1.8M |
| Q4 2024 | $2.4M |
TBCH spent $29M buying back its own shares over the past year, up 50% from the year before.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over TBCH on leverage, with a lower net debt burden relative to earnings.
TBCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.2x | High |
| Q2 2026 | 4.7x | High |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 0.8x | Very low |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.4x | Healthy |
TBCH's net debt is about 5.2 years of its operating earnings (EBITDA), up from 1.3 years a year ago.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
TBCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.8 | Neutral |
| Stochastic | 76.0 | Neutral |
TBCH's weekly RSI is 64 (neutral) and its Stochastic is 76 (neutral).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
TBCH PE vs Technology Sector
| Metric | TBCH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
TBCH has no meaningful PE right now: it lost money over the past year.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
TBCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.9 | 11% above |
| 20 week MA | $13.6 | 21% above |
| 50 week MA | $12.9 | 28% above |
| 100 week MA | $13.8 | 19% above |
| 200 week MA | $13.1 | 26% above |
TBCH has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.
TBCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.91 | $24.7 | +178% |
| 2021 | $24.7 | $24.5 | -1.1% |
| 2022 | $24.5 | $6.99 | -71% |
| 2023 | $6.99 | $11.0 | +57% |
| 2024 | $11.0 | $16.9 | +55% |
| 2025 | $16.9 | $14.2 | -16% |
| 2026 YTD | $14.2 | $16.5 | +17% |
TBCH has the edge over NVDA on returns for 2026, with the stronger performance.